Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa M Cordes

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
European Urology Oncology|June 30, 2024
Enzalutamide Monotherapy in the EMBARK Trial Should Be Practice-changing and Existing Data Suggest How to Mitigate ToxicityLisa M Cordes, Fatima Karzai, Ravi A Madan
Current Opinion in Oncology|March 16, 2016
The evolving role of immunotherapy in prostate cancerLisa M Cordes, James L Gulley, Ravi A Madan
The Lancet. Oncology|July 1, 2021
The Dietary Supplement Health And Education Act: are we healthier and better informed after 27 years?Tristan M Sissung, Lisa M Cordes, William D Figg
Asian Journal of Andrology|March 28, 2018
Perspectives on the clinical development of immunotherapy in prostate cancerLisa M Cordes, James L Gulley, Ravi A Madan
The Oncologist|May 10, 2023
Relugolix in Clinical Practice: The Best Route for All?Lisa M Cordes, Fatima Karzai, William D Figg, et al.
JAAD Case Reports|July 29, 2017
Docetaxel extravasation: Pathologic correlation and treatment with intralesional steroidsJohn W Roman, Michelle A Ojemuyiwa, Lisa M Cordes, et al.
The Oncologist|April 17, 2020
Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for ManagementJaydira Del Rivero, Lisa M Cordes, Joanna Klubo-Gwiezdzinska, et al.
The Oncologist|November 5, 2020
In ReplySriram Gubbi, Lisa M Cordes, Joanna Klubo-Gwiezdzinska, et al.
Clinical Case Reports|January 31, 2020
Neurotoxicities associated with checkpoint inhibitors: Two case reports and a review of the literatureLisa M Cordes, Nicole N Davarpanah, Lauren B Reoma, et al.
The Oncologist|August 1, 2021
Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single-Dose Administration Under Fasting Conditions in Prostate CancerLisa M Cordes, Keith T Schmidt, Cody J Peer, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
European Urology Oncology|June 30, 2024
Enzalutamide Monotherapy in the EMBARK Trial Should Be Practice-changing and Existing Data Suggest How to Mitigate ToxicityLisa M Cordes, Fatima Karzai, Ravi A Madan
Current Opinion in Oncology|March 16, 2016
The evolving role of immunotherapy in prostate cancerLisa M Cordes, James L Gulley, Ravi A Madan
The Lancet. Oncology|July 1, 2021
The Dietary Supplement Health And Education Act: are we healthier and better informed after 27 years?Tristan M Sissung, Lisa M Cordes, William D Figg
Asian Journal of Andrology|March 28, 2018
Perspectives on the clinical development of immunotherapy in prostate cancerLisa M Cordes, James L Gulley, Ravi A Madan
The Oncologist|May 10, 2023
Relugolix in Clinical Practice: The Best Route for All?Lisa M Cordes, Fatima Karzai, William D Figg, et al.
JAAD Case Reports|July 29, 2017
Docetaxel extravasation: Pathologic correlation and treatment with intralesional steroidsJohn W Roman, Michelle A Ojemuyiwa, Lisa M Cordes, et al.
The Oncologist|April 17, 2020
Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for ManagementJaydira Del Rivero, Lisa M Cordes, Joanna Klubo-Gwiezdzinska, et al.
The Oncologist|November 5, 2020
In ReplySriram Gubbi, Lisa M Cordes, Joanna Klubo-Gwiezdzinska, et al.
Clinical Case Reports|January 31, 2020
Neurotoxicities associated with checkpoint inhibitors: Two case reports and a review of the literatureLisa M Cordes, Nicole N Davarpanah, Lauren B Reoma, et al.
The Oncologist|August 1, 2021
Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single-Dose Administration Under Fasting Conditions in Prostate CancerLisa M Cordes, Keith T Schmidt, Cody J Peer, et al.
Pageof 4